Adrenomedullin affects two signal transduction pathways and the migration in retinal pigment epithelial cells

Investigative Ophthalmology and Visual Science

Volumn 45, Issue 5, 2004, Pages 1507-1513

  Huang, Wei ^a,b   Wang, Lin ^a   Yuan, Ming ^a   Ma, Jixian ^a   Hui, Yannian ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; BUFFER; CALCIUM ION; CHEMOTACTIC FACTOR; CYCLIC AMP; CYCLIC GMP; FIBRONECTIN; FLUORESCENT DYE; LAMININ; POLY DEXTRO LYSINE; ANILINE DERIVATIVE; CALCIUM; FLUO 3; FORSKOLIN; N(G) NITROARGININE METHYL ESTER; PEPTIDE; VASODILATOR AGENT; XANTHENE DERIVATIVE;

ARTICLE; CALCIUM CELL LEVEL; CELL ADHESION; CELL MIGRATION; CELL STIMULATION; CONCENTRATION RESPONSE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; ENZYME IMMUNOASSAY; FETAL CALF SERUM; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; PIGMENT EPITHELIUM; PRIORITY JOURNAL; REGULATORY MECHANISM; SECOND MESSENGER; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UPREGULATION; VITREORETINOPATHY; CALCIUM SIGNALING; CELL CULTURE; CELL MOTION; CONFOCAL MICROSCOPY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; METABOLISM;

ADRENOMEDULLIN; ANILINE COMPOUNDS; CALCIUM; CALCIUM SIGNALING; CELL ADHESION; CELL MOVEMENT; CELLS, CULTURED; CYCLIC AMP; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FORSKOLIN; HUMANS; IMMUNOENZYME TECHNIQUES; MICROSCOPY, CONFOCAL; NG-NITROARGININE METHYL ESTER; PEPTIDES; PIGMENT EPITHELIUM OF EYE; SECOND MESSENGER SYSTEMS; UP-REGULATION; VASODILATOR AGENTS; XANTHENES;

EID: 2442690670     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.03-0731     Document Type: Article

References (38)

1. Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993;192:553-560.
2. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev. 2000;21:138-167.
3. Withers DJ, Coppock HA, Seufferlein T, Smith DM, Bloom SR, Rozengurt E. Adrenomedullin stimulates DNA synthesis and cell proliferation via elevation of cAMP in Swiss 3T3 cells. FEBS Lett. 1996;378:83-87.
4. Yeung VT, Ho SK, Nicholls MG, Cockram CS. Adrenomedullin, a novel vasoactive hormone, binds to mouse astrocytes and stimulates cyclic AMP production. J Neurosci Res. 1996;46:330-335.
5. Gumusel B, Chang JK, Hao Q, et al. Adrenotensin: an adrenomedullin gene product contracts pulmonary blood vessels. Peptides. 1996;17:461-465.
6. Tanaka M, Kitamura K, Ishizaka Y, et al. Plasma adrenomedullin in various diseases and exercise-induced change in adrenomedullin in healthy subjects. Intern Med. 1995;34:728-733.
7. Moody TW, Miller MJ, Martinez A, Unsworth E, Cuttitta F. Adrenomedullin binds with high affinity, elevates cyclic AMP, and stimulates c-fos mRNA in C6 glioma cells. Peptides. 1997;18:1111-1115.
8. Chini EN, Choi E, Grande JP, Burnett JC, Dousa TP. Adrenomedullin suppresses mitogenesis in rat mesangial cells via cAMP pathway. Biochem Biophys Res Commun. 1995;215:868-873.
9. Barker S, Kapas S, Corder R, Clark AJ. Adrenomedullin acts via stimulation of cyclic AMP and not via calcium signalling in vascular cells in culture. J Hum Hypertens. 1996;10:421-423.
10. Takahashi K. Adrenomedullin: from a pheochromocytoma to the eyes. Peptides. 2001;22:1691.
11. Udono T, Totsune K, Takahashi K, et al. Increased expression of adrenomedullin mRNA in the tissues of intraocular and orbital tumors. Am J Ophthalmol. 2000;129:555-556.
12. Yousufzai SY, Ali N, Abdel-Latif AA. Effects of adrenomedullin on cyclic AMP formation and on relaxation in iris sphincter smooth muscle. Invest Ophthalmol Vis Sci. 1999;40:3245-3253.
13. Udono T, Takahashi K, Nakayama M, et al. Adrenomedullin in cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2000;41:1962-1970.
14. Udono T, Takahashi K, Nakayama M, et al. Induction of adrenomedullin by hypoxia in cultured retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2001;42:1080-1086.
15. Kirchhof B, Kirchhof E, Ryan SJ, Dixon JF, Barton BE, Sorgente N. Macrophage modulation of retinal pigment epithelial cell migration and proliferation. Graefes Arch Clin Exp Ophthalmol. 1989;227:60-66.
16. Udono T, Takahashi K, Takano S, Shibahara S, Tamai M. Elevated adrenomedullin in the vitreous of patients with proliferative vitreoretinopathy. Am J Ophthalmol. 1999;128:765-767.
17. Hackett S, Friedman Z, Campochiaro PA. Cyclic 3′,5′-adenosine monophosphate modulates retinal pigment epithelial cell migration in vitro. Arch Ophthalmol. 1986;104:1688-1692.
18. Horio T, Kohno M, Kano H, et al. Adrenomedullin as a novel antimigration factor of vascular smooth muscle cells. Circ Res. 1995;77:660-664.
19. Han QH, Hui YN, Du HJ, Zhang WJ, Ma JX, Wang SY. Migration of retinal pigment epithelial cells in vitro modulated by monocyte chemotactic protein-1: enhancement and inhibition. Graefes Arch Clin Exp Ophthalmol. 2001;239:531-538.
20. Hinton DR, He S, Graf K, et al. Mitogen-activated protein kinase activation mediates PDGF-directed migration of RPE cells. Exp Cell Res. 1998;239:11-15.
21. Jin M, He S, Worpel V, Ryan SJ, Hinton DR. Promotion of adhesion and migration of RPE cells to provisional extracellular matrices by TNF-alpha. Invest Ophthalmol Vis Sci. 2000;41:4324-4332.
22. 2+ release. J Biol Chem. 1994;269:29621-29628.
23. Kogishi JI, Akimoto M, Mandai M, et al. Nitric oxide as a second messenger in phagocytosis by cultured retinal pigment epithelial cells. Ophthalmic Res. 2000;32:138-142.
24. 2+- signaling enhances rat gastric microvascular endothelial cell migration. J Physiol Pharmacol. 2000;51:799-811.
25. Machemer R, van Horn D, Aaberg TM. Pigment epithelial proliferation in human retinal detachment with massive periretinal proliferation. Am J Ophthalmol. 1978;85:181-191.
26. Limb GA, Little BC, Meager A, et al. Cytokines in proliferative vitreoretinopathy. Eye. 1991;5:686-693.
27. Connor TB Jr, Roberts AB, Sporn MB, et al. Correlation of fibrosis and transforming growth factor-β type 2 levels in the eye. J Clin Invest. 1989;83:1661-1666.
28. Abu el-Asrar AM, Van Damme J, Put W, et al. Monocyte chemotactic protein-1 in proliferative vitreoretinal disorders. Am J Ophthalmol. 1997;123:599-606.
29. Robbins SG, Mixon RN, Wilson DJ, et al. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. Invest Ophthalmol Vis Sci. 1994;35:3649-3663.
30. Liversidge J, Grabowski P, Ralston S, et al. Rat retinal pigment epithelial cells express an inducible form of nitric oxide synthase and produce nitric oxide in response to inflammatory cytokines and activated T cells. Immunology. 1994;83:404-409.
31. Kohno M, Yasunari K, Minami M, et al. Regulation of rat mesangial cell migration by platelet-derived growth factor, angiotensin II, and adrenomedullin. J Am Soc Nephrol. 1999;10:2495-2502.
32. Schwab A. Function and spatial distribution of ion channels and transporters in cell migration. Am J Physiol. 2001;280:R739-R747.
33. Smith-Thomas L, Haycock JW, Metcalfe R, et al. Involvement of calcium in retinal pigment epithelial cell proliferation and pigmentation. Curr Eye Res. 1998;17:813-822.
34. Baldridge WH, Fischer AJ. Nitric oxide donor stimulated increase of cyclic GMP in the goldfish retina. Vis Neurosci. 2001;18:849-856.
35. Koga T, Zhang WY, Gotoh T, Oyadomari S, Tanihara H, Mori M. Induction of citrulline-nitric oxide (NO) cycle enzymes and NO production in immunostimulated rat RPE-J cells. Exp Eye Res. 2003;76:15-21.
36. Kutty RK, Kutty G, Hooks JJ, Wiggert B, Nagineni CN. Transforming growth factor-beta inhibits the cytokine-mediated expression of the inducible nitric oxide synthase mRNA in human retinal pigment epithelial cells. Biochem Biophys Res Commun. 1995;215:386-393.
37. Holtkamp GM, Kijlstra A, Peek R, de Vos AF. Retinal pigment epithelium-immune system interactions: cytokine production and cytokine-induced changes. Prog Retin Eye Res. 2001;20:29-48.
38. Charteris DG. Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol. 1995;79:953-60.